Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 6/20 | 0.46 |
| ▸ | TYMP | P19971 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1723958 | 0.94 | GLA (0.76) | GLATSHRGPR84TYMPALDH1A1 | |
| SCHEMBL28213046 | 0.78 | ALDH1A1 (0.52) | GLAGPR84MAPTALDH1A1PKM | |
| SCHEMBL4049125 | 0.77 | GLA (0.57) | GLATSHR | |
| SCHEMBL6685725 | 0.76 | GPR84 (0.51) | GLAGPR84TYMPALDH1A1PKM | |
| SCHEMBL251649 | 0.76 | TYMP (0.47) | GLATSHRGPR84TYMPALDH1A1 | |
| SCHEMBL10396476 | 0.72 | GLA (0.47) | GLAMAPTALDH1A1PKMHPGD | |
| SCHEMBL5712557 | 0.72 | ALDH1A1 (0.48) | GPR84ALDH1A1PKMHPGD | |
| SCHEMBL16852654 | 0.71 | GLA (0.61) | GLATSHRMAPTALDH1A1 | |
| SCHEMBL9414255 | 0.69 | PARP1 (0.46) | GLAGPR84TYMPALDH1A1 | |
| SCHEMBL15115442 | 0.68 | EPHX2 (0.60) | GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005704-A1 | SUBSTITUTED ARYLIMIDAZOLONE AND TRIAZOLONE AS INHIBITORS OF VASOPRESSIN RECEPTORS | BAYER PHARMA AKTIENGESELLSHAFT (DE) | 2013-01-03 | — | — | US | disclosed |
| US-20120208852-A1 | Heterocyclic-substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-16 | — | — | US | disclosed |
| US-20120053218-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-01 | — | — | US | disclosed |
| US-8084481-B2 | Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | BAYER HEALTHCARE AG (DE) | 2009-12-17 | — | — | US | disclosed |
| WO-2007133820-A2 | DIARYL TRIAZOLONES AS CB1 ANTAGONISTS | NEUROGEN CORPORATION (US) | 2007-11-22 | — | — | WO | disclosed |
| US-5436252-A | Antiischemic agents, stroke, Alzheimer's or Parkinson's diseases | MERRELL DOW PHARMACEUTICALS INC. (US) | 1995-07-25 | — | — | US | disclosed |
| EP-0273310-B1 | 5-Aryl-3H-1,2,4-triazol-3-ones and their use as anticonvulsants | MERRELL DOW PHARMA (US) | 1995-06-21 | — | — | EP | disclosed |
| EP-0273309-B1 | 5-Aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders | MERRELL DOW PHARMA (US) | 1995-01-11 | — | — | EP | disclosed |
| US-4919708-A | Haloalkyl triazolinones and herbicidal use thereof | FMC CORPORATION (US) | 1990-04-24 | — | — | US | disclosed |
| US-4846875-A | PLANT GROWTH REGULATORS | FMC CORPORATION (US) | 1989-07-11 | — | — | US | disclosed |
| EP-0273310-A2 | 5-Aryl-3H-1,2,4-triazol-3-ones and their use as anticonvulsants | MERRELL PHARMACEUTICALS INC. (US) | 1988-07-06 | — | — | EP | disclosed |
| EP-0273309-A2 | 5-Aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-07-06 | — | — | EP | disclosed |
| EP-0221083-A1 | HALOALKYL TRIAZOLINONES | FMC Corporation (US) | 1987-05-13 | — | — | EP | disclosed |
| WO-1986004481-A2 | HALOALKYL TRIAZOLINONES | FMC CORPORATION (US) | 1986-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | AVPR2, AVPR1A, AVPR1B | GLA 3799/4885TSHR 43/4885GPR84 339/4885 |
| US-20120053218-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN-RECEPTOR INHIBITORS FOR TREATING CARDIAC INSUFFICIENCY | AVPR2, AVPR1B, AVPR1A | GLA 3298/4885TSHR 78/4885GPR84 651/4885 |
| US-20120208852-A1 | Heterocyclic-substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | AADAC, NAT1, TNNI3 | GLA 785/4885TSHR 2383/4885GPR84 3596/4885 |
| US-20130005704-A1 | SUBSTITUTED ARYLIMIDAZOLONE AND TRIAZOLONE AS INHIBITORS OF VASOPRESSIN RECEPTORS | AVPR2, AVPR1A, AVPR1B | GLA 3799/4885TSHR 43/4885GPR84 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.